Ezepheno

**Ezepheno** is an oral fixed-dose lipid-lowering combination of **ezetimibe** and **fenofibrate** developed by Hyundai Pharmaceutical. Ezetimibe inhibits intestinal cholesterol absorption through Niemann-Pick C1-Like 1, while fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that improves triglyceride-rich lipoprotein metabolism. The product was evaluated as HDDO-1756 against loose co-administration of its individual components in a completed Phase 1 pharmacokinetic study and was subsequently approved in South Korea as Ezepheno for mixed hyperlipidemia. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04755894))

Brand names

Ezepheno에제페노정

Other names

ezetimibe + fenofibrate